Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Seattle Children's Hospital
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- ADHD Rating Scale - IV
Study Overview
Brief Summary
The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).
Detailed Description
To evaluate the safety and tolerability of low to moderate dose effects of Quillivant XR (liquid methylphenidate) and to observe changes in ADHD symptoms and functional outcomes in children with ASD and ADHD. The investigators propose to investigate the low to moderate dose range of methylphenidate compared with a very low dose with a gradual dose escalation schedule because children with ASD have been found to be more sensitive to the adverse effects of methylphenidate (especially in medium to high doses) than children without ASD.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 5 Years to 16 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •A clinical diagnosis of Autistic disorder or Asperger's disorder by DSM-IV or Autism Spectrum Disorder by DSM-V.
- •A DSM-V diagnosis of ADHD based upon the K-SADS-P.
- •Clinical Global Impressions - Severity for ADHD (CGI-S-ADHD) rating >
- •Findings on physical exam, labs and ECG are judged to be normal for age with pulse and blood pressure within 95% of age and gender mean.
- •Informed consent by a parent or legal guardian, and assent for children with developmental age 7 years or older.
- •At least one parent fluent in English
Exclusion Criteria
- •History of Seizure disorder (Febrile seizures are non-exclusionary).
- •History of Intellectual Disability (IQ< 70)
- •Treatment with MAO Inhibitor (or within 14 days following discontinuation of MAO Inhibitor).
- •Other psychotropic medication other than stable dose of Selective Serotonin Reuptake Inhibitors, which is permitted)
- •Known to be hypersensitive to methylphenidate, or other components of Quillivant XR
- •Cardiac or other medical contraindications for stimulant trial (e.g., family history of heart attack at age younger than 40 years, personal history of heart disease, history of fainting while exercising, structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac problems. If any doubt, children will be referred to a cardiologist for a cardiac clearance.
- •Raynaud's disease
- •Pregnancy or Breast-feeding.
Arms & Interventions
Very Low Dose Quillivant XR
Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a very low dose level for 6 weeks.
Intervention: Very Low Dose Quillivant XR (Drug)
Low Dose Quillivant XR
Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a low dose level for 6 weeks.
Intervention: Low Dose Quillivant XR (Drug)
Moderate dose Quillivant XR
Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a moderate dose level for 6 weeks.
Intervention: Moderate Dose Quillivant XR (Drug)
Outcomes
Primary Outcomes
ADHD Rating Scale - IV
Time Frame: once a week for 6 weeks
Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms.
Secondary Outcomes
- Clinical Global Impressions-ADHD - Severity(once a week for 6 weeks)
- Clinical Global Impression - Improvement (CGI-I)(once a week for 6 weeks)
Investigators
Mark Stein
Director of ADHD/Related Disorders Program
Seattle Children's Hospital